Danbury firm assists in viral vaccine trial

AstraZeneca will use a clinical trial platform from Iqvia to test a vaccine candidate for COVID-19 that has drawn a $1.2 billion investment from the federal government, one of several entering trials later this year under the Operation Warp Speed program overseen by the U.S. Department of Health & Human Services. Iqvia has corporate offices in Danbury and Research Triangle Park, N.C., with the company providing a range of services for drug trials as well as data on the pharmaceutical market. AstraZeneca expects to begin enrolling patients in its trial this summer.